**Star News, Aibo Medical (688050) replied to investors' concerns on the investor relations platform on February 28.
Investors:When does the buyback start and how is it progressing.
Secretary of the Board of Directors of Aibo Medical:Dear investors, hello! The company has been published on February 24, 2024 on the Shanghai **Stock Exchange** (www.sse.com.CN) disclosed the "Announcement on the Repurchase of the Company's Shares by Centralized Bidding Transaction", and is currently going through the repurchase business procedures in accordance with relevant laws and regulations. Thank you for your support to Aibo Medical.
Investors:At the end of last year, the company won the bid for bifocal crystals, what is the current delivery progress, and whether there have been deliveries in the first quarter?
Secretary of the Board of Directors of Aibo Medical:Dear investors, hello! According to the relevant requirements, the centralized procurement you mentioned has not yet been implemented. Regarding the procurement results and implementation time, please refer to the announcement of the national organization of medical consumables joint procurement platform, thank you for your support to Aibo Medical!
Investors:What is the progress of the company's phakic intraocular lens PR listing review and what stage of approval has it reached?
Secretary of the Board of Directors of Aibo Medical:Dear investors, hello! The company's self-developed PR phakic intraocular lens has been submitted for registration in October 2023, and the progress of product research and development should be paid attention to the company's regular reports and announcements. Thank you for your interest in Aibo Medical!
Investors:Hello Secretary of the Board, can you disclose the progress of the approval of PRL, and at what step? Is it expected to be approved in the first quarter?
Secretary of the Board of Directors of Aibo Medical:Dear investors, hello! The company's self-developed PR phakic intraocular lens has been submitted for registration in October 2023, and the progress of product research and development should be paid attention to the company's regular reports and announcements. Thank you for your interest in Aibo Medical!
The above content is compiled by **Star based on public information, generated by algorithms, and has nothing to do with the position of this site. **Star strives but does not guarantee the accuracy, completeness, validity, timeliness of all or part of the content of the information (including but not limited to text, **audio, data and charts), if there is any problem, please contact us. This article is a compilation of data and does not constitute any investment advice for you.